A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma

Relapsed or refractory (rel/ref) classical Hodgkin lymphoma (cHL) remains a clinical challenge, with limited effective treatment options available after stem cell transplantation. In a multicenter phase 2 study, the efficacy of lenalidomide in rel/ref cHL patients was evaluated at a dose of 25 mg/d...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Fehniger, Todd A., Larson, Sarah, Trinkaus, Kathryn, Siegel, Marilyn J., Cashen, Amanda F., Blum, Kristie A., Fenske, Timothy S., Hurd, David D., Goy, Andre, Schneider, Stephanie E., Keppel, Catherine R., Wagner-Johnston, Nina D., Carson, Kenneth R., Bartlett, Nancy L.
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Hematology 2011
Ämnen:
Clinical Trials and Observations
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3217400/
https://ncbi.nlm.nih.gov/pubmed/21937701
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-07-362475
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk